Showing 2521-2530 of 4063 results for "".
- Glaukos Featured in Numerous Scientific Abstracts at the 2023 ASCRS Meetinghttps://modernod.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-the-2023-ascrs-meeting/2481578/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5–8, 2023 in San Diego. Glaukos will be exhibiting onsite at booth #1237. Key Glaucoma Prese
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&
- Advances in Holographic OCT Receive Heidelberg Engineering Xtreme Research Award 2023https://modernod.com/news/advances-in-holographic-oct-receive-heidelberg-engineering-xtreme-research-award-2023/2481565/Drs. Hendrik Spahr and Dierck Hillmann are being honored as winners of the 2023 Heidelberg Engineering Xtreme Research Award for their research on holographic optical coherence tomography (HOLO-OCT) and their ongoing effort to transfer this technology into clinical applications, according to
- CooperVision Seeks Proposals for 2023 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2023-science-and-technology-awards/2481549/CooperVision announced it is now accepting submissions for its 2023 Science and Technology Awards program. The program enables researchers around the world to explore new dimensions in vision care, with the goal of translating innovative ideas into practical solutions. Each year, Cooper
- Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023https://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-at-arvo-2023/2481541/Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-cryst
- CORE Demonstrates Advanced 3D Printing for Ocular Research at ARVO 2023https://modernod.com/news/core-demonstrates-advanced-3d-printing-for-ocular-research-at-arvo-2023/2481539/Scientists from the Centre for Ocular Research & Education (CORE) plan to unveil multiple advancements in 3D printing during the ARVO 2023 Annual Meeting in New Orleans. These innovations may widespread applications, with the potential to accelerate dev
- Vialase Announces 24-Month Safety Data from First-in-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT)https://modernod.com/news/vialase-announces-publication-of-24-month-safety-data-from-first-in-human-study-of-femtosecond-laser-image-guided-high-precision-trabeculotomy-flight/2481538/ViaLase announced the online publication of 24-month safety data from the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technolo
- Regeneron to Present New Data and Analyses of High-Dose Aflibercept at ARVO 2023https://modernod.com/news/regeneron-to-present-new-data-and-analyses-of-high-dose-aflibercept-at-arvo-2023/2481537/Regeneron Pharmaceuticals and its collaborator Bayer announced that aflibercept 8 mg and Eylea (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27. Among the presentations wi
- Allegro Ophthalmics Receives Approval from FDA for Design of Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd/2481527/Allegro Ophthalmics announced that the company has received agreement from the FDA under a Special Protocol Assessment (SPA) for the design of its phase 2b/3 clinical trial of risuteganib (Luminate) for the treatment of intermediate, dry age-related macular degeneration (AMD).